ASH1L and cancer: Furthermore, we identified an unrecognized regulatory axis of ASH1L-IGF-2 in invading cancer cells, which induces lipid-associated and angiogenic TAMs and maintains their pro-tumoral and anti-inflammatory phenotypes by enhancing OXPHOS (Fig. 8).